Retrieve available abstracts of 34 articles: HTML format
Single Articles
September 2025
BRUMBAUGH B, Westmeijer M, Thompson B, Holt A, et al Risk of Cutaneous T-cell Lymphoma in Patients with Autoimmune Diseases.
J Am Acad Dermatol. 2025 Sep 11:S0190-9622(25)02793. PubMed
August 2025
PANG Y, Thomas ZO, Ayanruoh LD, Enriquez GH, et al Skin microbiota differs between Black and White patients with cutaneous T-cell
lymphoma.
J Am Acad Dermatol. 2025 Aug 22:S0190-9622(25)02675. PubMed
NGUYEN AJ, Link JL, Johnson EF, Todd A, et al Assessing the utility of incorporation of clinical and histopathologic features
for risk stratification in plaque-stage folliculotropic mycosis fungoides: A
retrospective validation study.
J Am Acad Dermatol. 2025;93:398-405. PubMedAbstract available
GOYAL A, O'Leary D, Dabaja B, Weng WK, et al ASTCT and USCLC clinical practice recommendations for allogeneic stem cell
transplant in mycosis fungoides and Sezary syndrome.
J Am Acad Dermatol. 2025;93:387-397. PubMedAbstract available
April 2025
JIN Y Considerations on the Potential Link Between Dupilumab and Cutaneous T-cell
Lymphoma in Atopic Dermatitis.
J Am Acad Dermatol. 2025 Apr 4:S0190-9622(25)00563. PubMed
February 2025
ZOU M, Zhan K, Zhang Y, Li L, et al A systematic review of paraneoplastic pemphigus and paraneoplastic autoimmune
multiorgan syndrome: Clinical features and prognostic factors.
J Am Acad Dermatol. 2025;92:307-310. PubMedAbstract available
LIAO V, Lavin L, Pulitzer MP, Stuver R, et al Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for
atopic dermatitis: A retrospective cohort study from a single tertiary cancer
center.
J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00188. PubMed
December 2024
ACCETTA J, Gioe R, Rogers L, Chastain W, et al Cutaneous T cell lymphoma arising in patients treated with dupilumab: a case
series of 18 patients.
J Am Acad Dermatol. 2024 Dec 14:S0190-9622(24)03371. PubMed
ZVULUNOV A, Neale H, Stern J, Santaguida P, et al Approach to Mycosis Fungoides in children: Consensus-based recommendations.
J Am Acad Dermatol. 2024;91:1078-1085. PubMedAbstract available
September 2024
NGUYEN TV, Marcus AF, Sinnott SJ, Coleman A, et al Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated
with increased risk of cutaneous T cell lymphoma: a retrospective cohort study".
J Am Acad Dermatol. 2024 Sep 30:S0190-9622(24)02901. PubMed
CHEN C, Adeuyan O, Gordon ER, Schreidah CM, et al Impact of Fitzpatrick Skin Type on Narrowband UV-B Therapy Outcomes in Cutaneous
T-cell Lymphoma: A Retrospective Analysis.
J Am Acad Dermatol. 2024 Sep 19:S0190-9622(24)02866. PubMed
NEUBAUER ZJK, Brunner PM, Geskin LJ, Guttman E, et al Decoupling the Association of Dupilumab with Cutaneous T-Cell Lymphoma Reply to
"Dupilumab therapy for atopic dermatitis is associated with increased risk of
cutaneous T cell lymphoma: A retrospective cohort study.".
J Am Acad Dermatol. 2024 Sep 7:S0190-9622(24)02812. PubMed
August 2024
HASAN I, Zinn Z Response to Flynn et al. "Dupilumab therapy for atopic dermatitis is associated
with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
J Am Acad Dermatol. 2024 Aug 27:S0190-9622(24)02727. PubMed
CHO YT, Chu CY Comments on "dupilumab therapy for atopic dermatitis is associated with increased
risk of cutaneous T-cell lymphoma: a retrospective cohort study".
J Am Acad Dermatol. 2024 Aug 24:S0190-9622(24)02739. PubMed
FLYNN E, Leonard N, Svoboda R Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated
with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02726. PubMed
KRIDIN K, Ludwig RJ Reply to: "Dupilumab therapy for atopic dermatitis is associated with increased
risk of cutaneous T cell lymphoma: A retrospective cohort study".
J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02574. PubMed
CHEN TL, Ma SH Comments on the risk of cutaneous T cell lymphoma among patients with atopic
dermatitis receiving dupilumab.
J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02573. PubMed
July 2024
WU KJ, Wei KC Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated
with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
J Am Acad Dermatol. 2024 Jul 19:S0190-9622(24)02496. PubMed
FRIEDMAN A JAAD Game Changers: "Guidelines for phototherapy of mycosis fungoides and Sezary
syndrome: A consensus statement of the United States Cutaneous Lymphoma
Consortium".
J Am Acad Dermatol. 2024 Jul 17:S0190-9622(24)02503. PubMed
BRUMBAUGH BJ, Thompson BB, Holt A, Ebriani J, et al Delays in Diagnosis in Cutaneous T Cell Lymphoma: A Retrospective Study on
Clinical Course and Time to Death.
J Am Acad Dermatol. 2024 Jul 11:S0190-9622(24)01054. PubMed
SHIH PC, Wei JCC Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated
with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
J Am Acad Dermatol. 2024 Jul 11:S0190-9622(24)01041. PubMed
HASAN I, Zinn Z Response to Shih et al. "Dupilumab therapy for atopic dermatitis is associated
with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
J Am Acad Dermatol. 2024 Jul 10:S0190-9622(24)01046. PubMed
SAMIE F JAAD Game Changer: Photodynamic therapy with methyl-aminolevulinic acid for
paucilesional mycosis fungoides: A prospective open study and review of the
literature.
J Am Acad Dermatol. 2024;91:42. PubMed
April 2024
HASAN I, Parsons L, Duran S, Zinn Z, et al Dupilumab therapy for atopic dermatitis is associated with increased risk of
cutaneous T cell lymphoma: a retrospective cohort study.
J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566. PubMedAbstract available
POWERS CM, Piontkowski AJ, Orloff J, Pulsinelli J, et al Risk of lymphoma in patients with atopic dermatitis: A case-control study in the
All of Us database.
J Am Acad Dermatol. 2024 Apr 4:S0190-9622(24)00554. PubMed
March 2024
BANNER L, Rohan TZ, Zachian R, Gross T, et al Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate
cancers after diagnosis of primary cutaneous B-cell lymphoma: A SEER database
analysis.
J Am Acad Dermatol. 2024 Mar 19:S0190-9622(24)00505. PubMed
CHEN J, Martinez A, Shinohara MM Risk of Systemic Lymphoma in Patients with Cutaneous CD30+ Lymphoproliferative
Disorders: A Single Center Retrospective Cohort Analysis.
J Am Acad Dermatol. 2024 Mar 13:S0190-9622(24)00489. PubMed
DIAZ MJ, Haq Z, Tran JT, Abdi P, et al Psoriasis and non-Hodgkin's lymphoma in a diverse sample of U.S. adults: a
propensity matched case-control study.
J Am Acad Dermatol. 2024 Mar 5:S0190-9622(24)00440. PubMed
February 2024
OLSEN EA, Hodak E, Geskin L, Scarisbrick J, et al Bridging the specialty gap: Update on primary cutaneous lymphomas.
J Am Acad Dermatol. 2024;90:257-260. PubMed
HOOPER MJ, Veon FL, Enriquez GL, Nguyen M, et al Reply to Wu et al's US SEER analysis of sepsis in Black patients with CTCL.
J Am Acad Dermatol. 2024;90:e79. PubMed
January 2024
PATTERSON A JAAD Game Changer: "Early clinical manifestations of Sezary syndrome: A
multicenter retrospective cohort study".
J Am Acad Dermatol. 2024;90:121. PubMed
December 2023
NOCCO SE, Ewalt MD, Moy AP, Lewis NE, et al TRBC1 immunohistochemistry distinguishes cutaneous T-cell lymphoma from
inflammatory dermatitis: a retrospective analysis of 39 cases.
J Am Acad Dermatol. 2023 Dec 5:S0190-9622(23)03269. PubMed
October 2023
WU Y, Kang K, Sun X, Niu T, et al Increased risk of sepsis-caused death in Black patients with primary cutaneous
T-cell lymphoma and Burkitt lymphoma: A population study of the US SEER registry.
J Am Acad Dermatol. 2023 Oct 4:S0190-9622(23)02886. PubMed
September 2023
XIANG DH, Perlman KL, Brumbaugh B, Reardon RM, et al Prevalence of Autoimmune Diseases in Cutaneous B-Cell Lymphoma: A Retrospective
Cross Sectional Analysis.
J Am Acad Dermatol. 2023 Sep 18:S0190-9622(23)02829. PubMed
